Navigation Links
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Date:4/26/2012

ATLANTA, April 26, 2012 /PRNewswire/ -- UCB today announced interim results from the VITOBA™ (VImpaT® added to One Baseline AED) study, which showed that patients with less refractory partial-onset seizures treated with Vimpat® (lacosamide) C-V as add-on to monotherapy experienced seizure reduction.  These data were presented today at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans. 

VITOBA™ is a six-month prospective, non-interventional study of the efficacy, safety and tolerability of lacosamide when added to a single AED in patients with partial-onset seizures.  The study has a planned enrollment of 500 adult patients. This interim analysis included efficacy data for 99 patients and safety data for 109 patients.

The patient population in VITOBA™ reflects epilepsy patients treated in routine clinical practice. The majority of patients (73.4 percent) had received only 1-3 AEDs since diagnosis. The mean lacosamide maintenance dose was 250mg/day and the median was 200mg/day.

Compared to the overall VITOBA™ study population, patients treated with only one lifetime AED experienced the greatest benefit from add-on therapy with lacosamide:

  • 86.7 percent showed a 50 percent or greater reduction in seizure frequency (vs. 77.8 percent of the overall study population)
  • 80 percent showed a more than 75 percent or greater reduction in seizure frequency (vs. 64.6 percent of the overall study population)
  • 66.7 percent of those with a history of one lifetime AED experienced seizure freedom (vs. 43.4 percent of the overall study population)

Treatment emergent adverse events (TEAEs) included fatigue (11.9 percent), dizziness (10.1 percent) and convulsion (5.5 percent).

"While preliminary, this interim analysis is noteworthy because it reflects a real-worl
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 ... investing £2.5 million to help it meet the ... goods, healthcare, pharmaceuticals and logistics. Albion joins Shackleton ... ) Over the past 18 months ... its platform, its management team and its operations. ...
(Date:7/25/2014)... July 25, 2014  Depomed, Inc. (NASDAQ: ... quarter fiscal year 2014 financial results after the market ... a conference call beginning at 4:30 pm EDT, 1:30 pm PDT ... the call by dialing 877-317-6789 ( United States ... also be available via a live webcast on the ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
Breaking Medicine Technology:OmPrompt Funded for Customer Automation Management Market Expansion 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... and LONDON, Nov. 20 Boston Scientific Corporation (NYSE: ... received 510(k) clearance from the U.S. Food and Drug ... WallFlex® Fully Covered Esophageal Stent for the treatment of ... with resectable or non-resectable esophageal cancer. , (Photo: ...
... , HOUSTON, Nov. 20 Cyberonics, Inc. (Nasdaq: CYBX ... and Greg Browne, Chief Financial Officer, will present at the 21st ... December 2, 2009 at 12:00 PM EST. The conference session ... be presented. Piper Jaffray will host a webcast of the ...
Cached Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2
(Date:7/28/2014)... the years, many adolescents have been forced to accept ... in their knees. A new PhD study involving 3,000 ... carries on: , "We can see from the study ... of 12 and 19 experience problems with pain in ... knee pain in the front of the knee," says ...
(Date:7/28/2014)... at North Carolina State University is proposing a new ... ability with age, but don,t necessarily show declines in ... be how motivated older adults are to maintain focus ... wanted to explain the difference we see in cognitive ... professor of psychology at NC State and author of ...
(Date:7/28/2014)... July 28, 2014A group of researchers in Taiwan has ... to detect an early complication of diabetes sooner, when ... safe and effective in clinical trials, it may pave ... treatment of this complication, called diabetic autonomic neuropathy, which ... Type 2 diabetes. The condition progressively affects the autonomic ...
(Date:7/28/2014)... of Bradford, UK, have devised a simple blood ... have cancer or not. , The test ... presenting with certain symptoms, saving time and preventing costly ... being carried out. Alternatively, it could be a useful ... a cancer that is currently hard to diagnose. ...
(Date:7/28/2014)... the European project SOPHIE has evaluated the relationship ... inequalities in health in Europe. The results show ... southern Europe) and countries with contradictory policies (Eastern ... women reported poorer health than men. Health inequalities ... women present a 27% higher risk of having ...
Breaking Medicine News(10 mins):Health News:Many people never grow out of their growing pains 2Health News:Motivation explains disconnect between testing and real-life functioning for seniors 2Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Potential 'universal' blood test for cancer discovered 2Health News:Potential 'universal' blood test for cancer discovered 3Health News:Gender inequalities in health: A matter of policies 2
... Patients believe,that access to their prescription medications ... by unfair reimbursement practices and,policies to their community ... polling company(TM), inc., "Our patients have it ... in their health care," said Stephen Giroux, PD, ...
... Study finds false positives occur 9.2% of the time in ... doctors in the emergency room believe that someone is having ... time, a new study indicates. , Given that minutes matter ... in this setting, that percentage is tolerable, say researchers from ...
... An international team of researchers led by Mayo Clinic have ... a virus to destroy cancer cells that spread from primary ... system. In addition, their study shows that this technology could ... cancer recurrence. , The study appeared in the Dec. 9 ...
... for patients with spinal cord injuries can stimulate ... compensatory changes in the brain, say Canadian researchers. ... function and the ability to walk. , A ... the remarkable benefits of rehabilitation training after a ...
... Island Hospital has received a renewal of a $1.5 million ... examine the driving abilities of elderly drivers. The study is ... elders in their natural driving environments. , Under the ... Alzheimers Disease and Memory Disorders Center at Rhode Island Hospital, ...
... of North America 93rd ... Scientific Assembly and Annual Meeting, NEWPORT NEWS, Va., Dec. ... North America 93rd Scientific,Assembly and Annual Meeting demonstrated the value ... to mammography and,breast ultrasound. The study, performed by Dr. Jean ...
Cached Medicine News:Health News:Study Indicates Strong Consumer Preference to Fix Medicare Part D and Medicaid Flaws Threatening Access to Prescription Drugs 2Health News:Study Indicates Strong Consumer Preference to Fix Medicare Part D and Medicaid Flaws Threatening Access to Prescription Drugs 3Health News:Diagnosis of Heart Attack Can Be Wrong 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 3Health News:Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord 2Health News:Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 2Health News:Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 3
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... Ad-Techs Intraoperative Electrodes share ... electrodes. The main difference is ... discs are numbered to assist ... electrodes are designed for use ...
... the Selenia full field digital mammography ... new era in the world of ... innovation combines the latest advances in ... management capabilities to bring you the ...
... The P3000 heralds a new concept in ... binocular infrared optical system developed for the P2000. ... standard in which we have paid particular attention ... Our new system is extremely flexible, allowing ...
Medicine Products: